TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 09, 2023 16:02 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
TRACON to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 9, 2023
October 31, 2023 16:02 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned
September 18, 2023 08:00 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences
September 05, 2023 16:02 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023 16:02 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023
August 02, 2023 16:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma
July 11, 2023 08:00 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, July 11, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial
June 20, 2023 08:00 ET
|
TRACON Pharmaceuticals, Inc.
Single Agent Envafolimab ORR Exceeded Futility Rule that will be Applied at the Interim Efficacy Analysis Expected in Q3 Continuing Double-Digit Objective Response Rate (ORR) by Blinded...
TRACON Pharmaceuticals to Present at the Maxim Group Healthcare Virtual Conference
June 16, 2023 08:00 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, June 16, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel...
TRACON Pharmaceuticals Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma
June 15, 2023 08:00 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, June 15, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel...